Education
About Us
Working with TipRanks
Follow Us
CBD Denver (CBDD)
:CBDD
Top Page
CBD Denver
(OTC:CBDD)
Select Model
Select Model
Rating:37Underperform
Price Target:―
CBD Denver faces significant financial and operational challenges, with high leverage and cash flow issues as primary concerns. The lack of technical indicators and an extremely high P/E ratio indicate potential overvaluation. Limited information from the earnings call adds uncertainty, resulting in a low overall stock score.
CBD Denver (CBDD) vs. SPDR S&P 500 ETF (SPY)
Market Cap
N/A
Dividend YieldN/A
Average Volume (3M)N/A
Price to Earnings (P/E)―
Beta (1Y)N/A
Revenue Growth-16.53%
EPS Growth-100.00%
CountryUS
EmployeesN/A
SectorHealthcare
Sector Strength45
IndustrySpecialty Retail
Share Statistics
EPS (TTM)0.00
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)-2.18
Price to Sales (P/S)0.78
P/FCF Ratio-33.19
Enterprise Value/Market CapN/A
Enterprise Value/Revenue0.00
Enterprise Value/Gross Profit0.00
Enterprise Value/Ebitda0.00
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
CBD Denver Business Overview & Revenue Model
Company DescriptionCBD of Denver Inc. engages in developing and commercializing cannabidiol (CBD) products. It is involved in the research, development, and distribution of premium hemp extract products. The company was formerly known as Verde Media Group, Inc. and changed its name to CBD of Denver Inc. in 2018. CBD of Denver Inc. is based in Centennial, Colorado. CBD of Denver Inc. operates as a subsidiary of Swiss Industry Ventures AG.
How the Company Makes MoneyCBD Denver makes money primarily through the sale of its CBD-infused products to both retail and wholesale customers. The company generates revenue by distributing its products through various channels, including online direct-to-consumer sales, partnerships with retail stores, and collaborations with distributors who supply to health and wellness outlets. Additionally, CBD Denver may engage in private labeling agreements, where it produces CBD products under different brand names for other companies, further diversifying its revenue streams. Strategic partnerships with hemp growers and technology providers for extraction processes also contribute to cost efficiencies and product quality, enhancing the company's profitability.
CBD Denver Financial Statement Overview
Summary
CBD Denver's financial performance shows some improvement in net income, but challenges remain with volatile revenue trends, negative EBIT margin, a high debt-to-equity ratio, and negative operating cash flow.Income Statement
CBD Denver shows some improvement in net income with a positive result in 2023 compared to prior years of losses. However, the company has experienced volatile revenue trends, with a significant decrease in revenue from 2021 to 2022, and a marginal increase in 2023. Margins remain a concern, with a negative EBIT margin in 2023, indicating ongoing operational challenges.35
Negative
Balance Sheet
The balance sheet reveals a concerning financial position, with negative stockholders' equity in recent years, indicating potential solvency issues. The company has a high debt-to-equity ratio, exacerbated by negative equity, suggesting significant leverage and financial risk.20
Very Negative
Cash Flow
Operating cash flow remains negative, indicating cash management issues, despite some improvement in 2023. Free cash flow data is incomplete, limiting analysis. The positive shift in financing cash flow points to reliance on external funding.25
Negative
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 3.75M | 2.98M | 2.34M | 22.85M | 15.99M |
| Gross Profit | 218.16K | 165.48K | -670.00K | 240.52K | 1.41M |
| EBITDA | 85.25K | 697.77K | -3.25M | -300.00K | 1.21M |
| Net Income | -79.93K | 583.58K | -3.25M | -236.00K | 779.14K |
Balance Sheet | |||||
| Total Assets | 40.76K | 128.30K | 28.04K | 1.97M | 2.74M |
| Cash, Cash Equivalents and Short-Term Investments | 35.12K | 36.55K | 28.04K | 91.51K | 82.65K |
| Total Debt | 1.06M | 1.06M | 949.38K | 781.68K | 253.21K |
| Total Liabilities | 1.38M | 1.48M | 2.00M | 1.72M | 1.94M |
| Stockholders Equity | -1.34M | -1.35M | -1.97M | 247.66K | 798.37K |
Cash Flow | |||||
| Free Cash Flow | -87.85K | -31.44K | -759.21K | -723.90K | 60.95K |
| Operating Cash Flow | -87.85K | -31.44K | -759.21K | -723.90K | 60.95K |
| Investing Cash Flow | 0.00 | 11.08K | 0.00 | 0.00 | -15.98K |
| Financing Cash Flow | 86.42K | 10.97K | 731.00K | 855.49K | 310.00 |
CBD Denver Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
68 Neutral | $478.77M | 16.32 | 39.74% | 9.42% | -8.56% | -57.78% | |
54 Neutral | $51.52M | 147.69 | 1.05% | 17.74% | -2.07% | -61.05% | |
53 Neutral | $1.05B | ― | -2.48% | ― | -2.83% | 97.94% | |
52 Neutral | $100.42M | ― | -37.31% | ― | -20.55% | -2.43% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | $258.99M | ― | -176.08% | ― | -9.95% | 39.66% | |
37 Underperform | ― | ― | ― | ― | -16.53% | -100.00% |
* Healthcare Sector Average
CBDD
CBD Denver
―
―
―
NHTC
Natural Health Trends
4.45
-0.63
-12.40%
GRWG
GrowGeneration
1.68
-0.43
-20.38%
CHPT
ChargePoint Holdings
10.85
-14.15
-56.60%
BWMX
Betterware de Mexico
12.92
1.83
16.50%
WOOF
Petco Health and Wellness Company
3.69
-0.91
-19.78%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.